Pfizer Inc. (PFE)
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Obesity drugs, particularly via Metsera, represent a potential $150B TAM, though market skepticism persists until Phase III data matures.
Pfizer: The Rebound Looks Unsustainable
Pfizer Inc. delivered a 17% total return since early November, but I remain cautious. I do not recommend buying PFE stock, as the recent rally is not supported by fundamentals. Valuation analysis and mitigating factors do not justify a bullish stance on PFE.
Pfizer: A Great Opportunity Post Earnings
Pfizer remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. PFE's non-COVID portfolio posted 6% operational growth in 2025, with international markets and Pfizer CentreOne driving resilience. Productivity initiatives are on track to deliver $7.2B in net cost savings, supporting margin improvement despite patent cliff and pricing headwinds.
Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?
PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.
Is Pfizer Stock Now A Value Trap?
Pfizer (PFE) is confronting challenges. Even the most prominent companies are not beyond reach.
Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
Pfizer agreed to accept $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?
PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.
Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity
Pfizer (PFE) remains a 'Hold' due to near-term headwinds, including a $1.5B patent cliff in 2026 and declining Covid-19 revenues. PFE's long-acting GLP-1 obesity program, bolstered by the Metsera acquisition, shows promise but lacks approval until at least 2028. Excluding Covid-19 products, PFE achieved 6% operational revenue growth in 2025, but total revenues declined 2% year-over-year.
Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
Pfizer made one thing clear this week: It's officially back in the obesity race.
Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
Pfizer Inc. NYSE: PFE helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report.
